Skip to main content
SpringerLink
Log in

Elements of applied immunology for the intensive care unit and chronic uremia-related disorders

  • Chapter
Critical Care Nephrology

  • 33 Accesses

Abstract

Independent of its cause, end stage renal disease (ESRD) is invariably associated with a major dysregulation of both nonspecific and specific immunity. Since the first report — in the late 50s — of a prolonged survival of skin homografts in ESRD patients [1], a state of immunodeficiency has been widely confirmed in uremics as recently reviewed in [2]. ESRD patients are electively susceptible to infectious diseases involving intracellular pathogens, such as tuberculosis and listeriosis, respond poorly to viral infections and to vaccines against viruses e.g. influenza and hepatitis B virus (HBV), and exhibit an abnormally high incidence of malignancy. Of note, maintenance dialysis does not improve, but rather worsens this state of immunodeficiency, and this holds true despite the significant improvement in the different materials used for hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Dammin GJ, Couch NP, Murray JE. Prolonged survival of skin homografts in uremic patients. Ann NY Acad Sci 1957; 64: 967–76.

    Article  PubMed  CAS  Google Scholar 

  2. Descamps-Latscha B, Jungers P. Immunological and chronic inflammatory abnormalities in end stage renal disease. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds). Replacement of Renal Function by Dialysis. Kluwer Academic Publishers, Dordrecht-Boston 1996: 1083–102.

    Chapter  Google Scholar 

  3. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P, Dayer JM. Balance between IL l ß, TNF-a, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T-cells, B-cells, and monocytes. J Immunol 1995; 154: 882–92.

    PubMed  CAS  Google Scholar 

  4. Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41: 1416–29.

    Article  PubMed  CAS  Google Scholar 

  5. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701.

    Article  PubMed  CAS  Google Scholar 

  6. Rinehart A, Collins AJ, Keans WF.. Host defenses and infectious complications in maintenance hemodialysis patients. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds). Replacement of Renal Function by Dialysis. Kluwer Academic Publishers, Dordrecht-Boston 1996: 1102–22.

    Google Scholar 

  7. Goldman M, Vanherweghem JL. Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. Adv Nephrol 1990; 19: 3 1532.

    Google Scholar 

  8. Haag-Weber M, Horl WH. Uremia and infection: mechanisms of impaired cellular host defense, editorial. Nephron 1993; 63: 125–31.

    Article  PubMed  CAS  Google Scholar 

  9. Mailloux LU, Bellucci AG, Wilkes BM, et al Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 1991; 18: 326–35.

    PubMed  CAS  Google Scholar 

  10. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. Nepron 1993; 1993: 95–100.

    Article  Google Scholar 

  11. Khan IH, Catto GRD. Long-term complications of dialysis. Infections. Kidney Int 1993; 43: S143–5148.

    Google Scholar 

  12. Jungers P, Delagneau JF, Prunet P, Crosnier J. Vaccination against hepatitis B in hemodialysis centers. Adv Nephrol 1982; 11: 303–15.

    Google Scholar 

  13. Crosnier J, Jungers P, Couroucé AM, et al Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II Haemodialysis patients. Lancet 1981; 1: 797–800.

    Article  PubMed  CAS  Google Scholar 

  14. Mioli VA, La Greca G. A special issue on virus hepatitis and the kidney. Nephron 1992; 61: 251–376.

    Article  Google Scholar 

  15. Benhamou E, Courouce AM, Jungers P, et al Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143–7.

    PubMed  CAS  Google Scholar 

  16. Jadoul M, Cornu C, van Ypersele de Strihou C, the UCL collaborative group. Incidence of risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int 1993; 44: 1322–6.

    Article  CAS  Google Scholar 

  17. Knudsen F, Wantzin P, Rasmussen K, et al Hepatitis C in dialysis patients: relationships to blood transfusions, dialysis and liver disease. Kidney Int 1993; 43: 13536.

    Article  Google Scholar 

  18. Chauveau P, Courroucé AM, Lemarec N, et al Antibodies to hepatitis C virus by second generation test in hemodialyzed patients. Kidney Int Suppl 1993; 43: S149–52.

    Google Scholar 

  19. Vitale C, Tricerri A, Marangella M, et al Epidemiology of hepatitis-C virus infection in dialysis units-1st-versus 2nd-generation assays. Nephron 1993; 64: 315–6.

    Article  PubMed  CAS  Google Scholar 

  20. Van Ypersele C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39: 1012–9.

    Article  Google Scholar 

  21. Zingraff J, Beyne P, Urena P, et al Influence of haemodialysis membranes on 132-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284–90.

    PubMed  CAS  Google Scholar 

  22. Chanard J, Vincent C, Caudwell V et al ß2-micro globulin metabolism in uremic patients who are under- going dialysis. Kidney Int Suppl 1993; 43: S83–7.

    Google Scholar 

  23. Zaoui PM, Stone WJ, Hakim RM. Effects of dialysis membranes on ß2-microglobulin production and cellular expression. Kidney Int 1990; 38: 962–8.

    Article  PubMed  CAS  Google Scholar 

  24. Linke RP, Keerling A, Rail A. Hemodialysis: demonstration of truncated 132-microglobulin in AB amyloid in situ. Kidney Int Suppl 1993; 43: S100–5.

    Google Scholar 

  25. Capeillere-Blandin C, Delaveau T, Descamps-Latscha B. Structural modifications of human ß2-microglobulin treated with oxygen-derived radicals. Biochem J 1991; 277: 175–82.

    PubMed  CAS  Google Scholar 

  26. Raska K JR, Raskova J, Shea SM, et al T-cell subsets and cellular immunity in end-stage renal disease. Am J Med 1983; 75: 734–40.

    Article  PubMed  Google Scholar 

  27. Chatenoud L, Dugas B, Beaurain G, et al Presence of preactivated T-cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci U S A 1986; 83: 7457–61.

    Article  PubMed  CAS  Google Scholar 

  28. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer Zum Buschenfelde KH. Impaired cellular immune responses in chronic renal failure: evidence for a T-cell defect. Kidney Int 1986; 29: 1209–14.

    Article  PubMed  CAS  Google Scholar 

  29. Tsakiris DJ, Watson MA. Degiannis D, Briggs WA. Association between blood transfusions, HLA-DRW6 and response to dinitrobenzene skin test. Transplantation Proc 1987; 19: 705–7.

    CAS  Google Scholar 

  30. Newberry WM, Sanford JP. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 1971: 50: 1262–71.

    Article  PubMed  CAS  Google Scholar 

  31. Kamata K, Okubo M, Sada M. Immunosuppressive factors in uraemic sera are composed of both dialysable and non dialysable components. Clin Exp Immunol 1983; 54: 277–81.

    PubMed  CAS  Google Scholar 

  32. Barsotti G, Bevilacqua G, Morelli E Et AL. Toxicity arising from guanidine compounds: role of methyl guanidine as uremic toxin. Kidney Int 1975; 7: S299.

    Google Scholar 

  33. Hörl WH, Haag-Weber M, Georgopoulos A Block LH. Physicochemical charcterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphoniclear cells. Proc Natl Acad Sci 1990; 6353–57.

    Google Scholar 

  34. Revillard JP. Immunologic alterations in chronic renal insufficiency. Adv Nephrol 1979; 8: 365–82.

    CAS  Google Scholar 

  35. Nelson DS, Penrose JM. Effect of hemodialysis and transplantation on inhibition of lymphocyte transformation by sera from uremic patients. Clin Immunol Immunopath 1975; 4: 143.

    Article  CAS  Google Scholar 

  36. Chouaib S, Bertoglio JH. Prostaglandin E as modulators of the immune response. Lymphokine Res 1988; 7: 237.

    CAS  Google Scholar 

  37. Sunder-Plassmann G, Heinz G, Wagner L, Prychzy B, Derfler K. T-cell selection and T-cell receptor variable beta-chain usage in chronic hemodialysis patients. Clin Nephrol 1992; 37: 252–9.

    PubMed  CAS  Google Scholar 

  38. Stachowski J, Pollok M, Burrichter H, Spithaler C, Baldamus CA. Does uremic environment down-regulate T-cell activation via TCR/CD3 antigen receptor complex? J Clin Lab Immunol 1991; 36: 15–21.

    PubMed  CAS  Google Scholar 

  39. Keown P, Descamps-Latscha B. In vitro suppression of cell-mediated immunity by ferroproteins and ferric salts. Cell Immunol 1983; 80: 257–66.

    Article  PubMed  CAS  Google Scholar 

  40. Bender BS, Curtis JL, Nagel JE, et al Analysis of immune status of hemodialyzed adults: association with prior transfusions. Kidney Int 1984; 26: 436–43.

    Article  PubMed  CAS  Google Scholar 

  41. De Sousa M. Immune functions in iron overload. Clin Exp Immunol 1989; 75: 1–6.

    PubMed  Google Scholar 

  42. Pfaffl W, Gross HJ, Neumeier D, Samtleben W, Gurland HJ. Lymphocyte subsets and delayed cutanious hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol 1988; 66: 195–204.

    PubMed  CAS  Google Scholar 

  43. Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. ASAIO Trans 1990; 36: M219–23.

    PubMed  CAS  Google Scholar 

  44. Grimm PC, Sinai-Trieman L, Sekiya NM, et al Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990; 38: 12–8.

    Article  PubMed  CAS  Google Scholar 

  45. Meuer SC, Hauer M, Kurz P, Meyer Zum Buschenfelde KH, Kohler H. Selective blockade of the antigenreceptor-mediated pathway of T-cell activation in patients with impaired primary immune responses. J Clin Invest 1987; 80: 743–9.

    Article  PubMed  CAS  Google Scholar 

  46. Stachowski J, Pollok M, Burrichter H, Baldamus CA. Immunodeficiency in ESRD-patients is linked to altered IL-2 receptor density on T-cell subsets. J Clin Lab Immunol 1991; 34: 171–7.

    PubMed  CAS  Google Scholar 

  47. Gerez L, Madar L, Shkolnik T, et al Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. Kidney Int 1991; 40: 266–72.

    Article  PubMed  CAS  Google Scholar 

  48. Walz G, Kunzendorf U, Josimovic-Alasevic O, et al Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentrations in end-stage renal failure. Nephron 1990; 56: 157–61.

    Article  PubMed  CAS  Google Scholar 

  49. Zaoui P, Green W, Hakim RM. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 1991; 39: 1020–26.

    Article  PubMed  CAS  Google Scholar 

  50. Descamps-Latscha B. The immune system in end stage renal disease. Curr Opin Nephrol Hypert 1993; 2: 883–91.

    Article  CAS  Google Scholar 

  51. Beaman M, Michael J, MacLennan IC, Adu D. T-cell independent and T-cell dependent antibody response in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 216–21.

    PubMed  CAS  Google Scholar 

  52. Guérin A, Buisson Y, Nutini MT, Saliou P, London G, Marchais S. Response to vaccination against tetanus in chronic haemodialyzed patients. Nephrol Dial Transplant 1992; 7: 323–6.

    PubMed  Google Scholar 

  53. Stoloff IL, Stout R, Myerson RM, Havens WP. Production of antibody in patients with uremia. N Engl J Med 1958; 259: 320.

    Article  PubMed  CAS  Google Scholar 

  54. Borradori L, Born B, Descoeudres C, Skvaril F, Morell A. Serum immunoglobulin levels and natural antibodies to haemophilus influenzae in hemodialysis patients: evidence for IgG subclass imbalances. Nephron 1990; 56: 35–9.

    Article  PubMed  CAS  Google Scholar 

  55. Rytel MW, Dailey MP, Schiffman G, Hoffmann RG, Piering WF. Pneumococcal vaccine immunization of patients with renal impairment. Proc Soc Exp Biol Med 1986; 182: 468–73.

    PubMed  CAS  Google Scholar 

  56. Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990; 4: 123–42.

    PubMed  CAS  Google Scholar 

  57. Abdulmassih Z, Duverlie G, Moriniere P, et al Response to influenza vaccine in uremic patients: relation to erythrocyte magnesium and the value of a second injection. Nephrologie 1987; 8: 23–6.

    PubMed  CAS  Google Scholar 

  58. Rautenberg P, Teifke I, Schlegelberger T, Ullmann U. Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination. Infection 1988; 16: 323–8.

    Article  PubMed  CAS  Google Scholar 

  59. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szuness W. Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 1984; 311: 496–501.

    Article  PubMed  CAS  Google Scholar 

  60. Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer Zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124–8.

    Article  PubMed  CAS  Google Scholar 

  61. Benhamou E, Courouce AM, Laplanche A, Jungers P, Tron JF, Crosnier J. Long-term results of hepatitis B vaccination in patients on dialysis. N Engl J Med 1986; 314: 1710–11.

    PubMed  CAS  Google Scholar 

  62. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988; 260: 1734–38.

    Article  PubMed  CAS  Google Scholar 

  63. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M, et al HLA-associated nonresponsiveness to hepatitis B vaccine. Tissue Antigens 1990; 35: 60–3.

    Article  PubMed  CAS  Google Scholar 

  64. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of non response to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990; 11: 385–7.

    Article  PubMed  CAS  Google Scholar 

  65. Alper CA, Kruskall MS, Marcus-Bagley D, et al Genetic pediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321: 708–12.

    Article  PubMed  CAS  Google Scholar 

  66. Caillat-Zucman S, Giminez JJ, Albouze G, et al HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int Suppl 1993; 43: S157–60.

    Google Scholar 

  67. Paczek L, Schaefer RM, Heidland A. Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Contrib Nephrol 1990; 87: 36–41.

    PubMed  CAS  Google Scholar 

  68. Sennesael JJ, Van Der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121–8.

    Article  PubMed  CAS  Google Scholar 

  69. Stachowski J, Pollock M, Burrichter H et al Relationships between TCR/CD3 receptor density on CD4 T cels and the anti-HBs antibody response to hepatitis B vaccination in ESRD patients. Nephrol Dial Transplant 1992; 7: 678–83.

    Google Scholar 

  70. Stachowski J, Pollock M, Barth C, Maciejewski, Baldamus CA. Nonresponsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant 1994; 9: 144–52.

    PubMed  CAS  Google Scholar 

  71. Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patienst who failed to respond to hepatitis B vaccination. Nephron 1988; 50: 133–6.

    Article  PubMed  CAS  Google Scholar 

  72. Meuer SC, Dumann H, Meyer Zum Buschenfelde KH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in innnunodeficient nonresponders to hepatitis B vaccination. Lancet 1989; 1: 15–8.

    Article  PubMed  CAS  Google Scholar 

  73. Quiroga JA, Castillo I, Porres JC, et al Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12: 661–3.

    Article  PubMed  CAS  Google Scholar 

  74. Dumann H, Meuer SC, Renschin G, Kohler H. Influence of thymopentin on antibody reponse, and monocyte and T-cell function in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1990; 55: 136–40.

    Article  PubMed  CAS  Google Scholar 

  75. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine (see comment). Lancet 1994; 344: 856–7.

    Article  PubMed  CAS  Google Scholar 

  76. Nolph KD, Husted FC, Sharp GC, Siemsen AW. Antibodies to nuclear antigens in patients undergoing long-term hemodialysis. Am J Med 1976; 60: 673–6.

    Article  PubMed  CAS  Google Scholar 

  77. Gagnon RF, Shuster J, Kaye M. Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis. J Clin Lab Immunol 1983; 11: 155–8.

    PubMed  CAS  Google Scholar 

  78. Rumpf KW, Seubert S, Seubert A Et AL. Association of ethylene-oxide-induced IgE antibodies with symptoms in dialysis patients. Lancet 1985; 2: 1385–7.

    Article  PubMed  CAS  Google Scholar 

  79. Descamps-Latscha B, Herbelin A, Nguyen AT, et al Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis. Kidney Int 1993; 43: 878–84.

    Article  PubMed  CAS  Google Scholar 

  80. Man NK, Zingraff J, Jungers P. Long-term Hemodialysis. Kluwer Academic Publishers, Dordrecht-Boston, 1995.

    Book  Google Scholar 

  81. Hallgren R, Venge P, Wikstrom B. Hemodialysis-induced increase in serum lactoferrin and serum eosinophil cationic protein as signs of local neutrophil and eosinophil degranulation. Nephron 1981; 29: 233–8.

    Article  PubMed  CAS  Google Scholar 

  82. Horl WH, Riegel W, Steinhauer HB, et al Granulocyte activation during hemodialysis. Clin Nephrol 1986; 26 Suppl 1.: S30–4.

    Google Scholar 

  83. Ritchey EE, Wallin JD, Shah SV. Chemiluminescence and superoxide anion production by leukocytes from chronic hemodialysis patients. Kidney Int 1981; 19: 349–58.

    Article  PubMed  CAS  Google Scholar 

  84. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C., Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985; 28: 158–67.

    Article  PubMed  CAS  Google Scholar 

  85. Descamps-Latscha B, Goldfarb B, Nguyen AT, et al Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. Nephron 1991; 59: 279–85.

    Article  PubMed  CAS  Google Scholar 

  86. Descamps-Latscha B, Herbelin A, Nguyen AT, Urena P. Respective influence of uremia and hemodialysis on whole blood phagocyte oxidative metabolism, and circulating interleukin-1 and tumor necrosis factor. Adv Exp Med Biol 1991; 297: 183–92.

    PubMed  CAS  Google Scholar 

  87. Richard MJ, Arnaud J, Jurkowitz C, Hachache T, Mefrahi H, Laporte F, Foret M, Favier A, Cordonnier D. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991; 57: 10–5.

    Article  PubMed  CAS  Google Scholar 

  88. Giardini O, Taccone-Gallucci M, Lubrano R, et al Evidence of red blood cell membrane lipid peroxidation in hemodialysis patients. Nephron 1984; 36: 2357.

    Google Scholar 

  89. Kikuchi Y, Koyama T, Koyama Y, et al Red blood cell deformability in renal failure.. Nephron 1982; 30: 814.

    Article  Google Scholar 

  90. Remuzzi G, Benigni A, Dodesini P, et al Reduced platelet thromboxane formation in uremia: evidence for a cyclo-oxygenase defect. J Clin Invest 1983; 71: 762–8.

    Article  PubMed  CAS  Google Scholar 

  91. Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1987; 1: 358–64.

    PubMed  CAS  Google Scholar 

  92. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–13.

    Article  PubMed  CAS  Google Scholar 

  93. Petrone WF, English DK, Wong K, McCord JM. Free radicals and inflammation: superoxide-dependent activation of a neutrophil chemotactic factor in plasma. Proc Natl Acad Sci U S A 1980; 77: 1159–63.

    Article  PubMed  CAS  Google Scholar 

  94. Carp H, Janoff A. In vitro suppression of serum elastase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes. J Clin Invest 1979; 63: 793–7.

    Article  PubMed  CAS  Google Scholar 

  95. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST. Oxidative autoactivation of latent collagenase by human neutrophils. Science 1985; 227: 747–9.

    Article  PubMed  CAS  Google Scholar 

  96. Del Maestro RF. An approach to free radicals in medicine and biology. Acta Physiol Scand Suppl 1980; 492: 153–68.

    PubMed  Google Scholar 

  97. Memmos DE, Eastwood JB, Harris E, de Wardener HE. The `shrinking man’ syndrome. Nephron 1982; 30: 106–9.

    Article  PubMed  CAS  Google Scholar 

  98. Himmerfarb J, Zaoui R Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis. A prospective, randomized controlled trial. Kidney Int 1992; 41: 388–95.

    Article  Google Scholar 

  99. Thylen P, Lundahl J, Fernvik E, Hed J, Svenson SB, Jacobson SH. Mobilization of an intracellular glycoprotein (Mac-1) on monocytes and granulocytes during hemodialysis. Am J Nephrol 1992; 12: 393–400.

    Article  PubMed  CAS  Google Scholar 

  100. Tielemans CL, Delville JP, Husson CP, et al Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993; 39: 158–65.

    PubMed  CAS  Google Scholar 

  101. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis: a prospective and cross sectional study. Kidney Int 1991; 39: 320–7.

    Article  PubMed  CAS  Google Scholar 

  102. Lewis SL, Van Epps DE, Chenoweth DE. C5a receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients. Clin Nephrol 1986; 26: 37–44.

    PubMed  CAS  Google Scholar 

  103. Tolkoff-Rubin NE, Rubin RH. Uremia and host defenses editorial; comment. N Engl J Med 1990; 322: 770–2.

    Article  PubMed  CAS  Google Scholar 

  104. Vanholder R, De Smet R, Hsu C, et al: Uremic toxicity. The middle molecule hypothesis revisited. Semin Nephrol 1994; 14: 205–18.

    PubMed  CAS  Google Scholar 

  105. Haag-Weber M, Horl WH. Altered cellular host defence in malnutrition and uremia. Contrib Nephrol 1992; 98: 105–1I.

    PubMed  CAS  Google Scholar 

  106. Paczek L, Czarkowska B, Schaefer L, Schaefer RM, Heidland A. Effect of beta 2-microglobulin on immunoglobulin production. Immunol Lett 1992; 33: 8791.

    Article  Google Scholar 

  107. Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S. Uremic toxicity. The middle molecule hypothesis revisited. Semin Nephrol 1994; 14: 205–18.

    PubMed  CAS  Google Scholar 

  108. Osaki K, Otsuka H, Uomizu K, Harada R, Otsuji Y, Hashimoto S. Monocyte-mediated suppression of mitogen responses of lymphocytes in uremic patients. Nephron 1983; 34: 87–92.

    Article  PubMed  CAS  Google Scholar 

  109. Ruddy MC, Rubin AL, Novogrodsky A, Stenzel KH. Decreased macrophage-mediated suppression of lymphocyte activation in chronic renal failure. Am J Med 1983; 75: 571–9.

    Article  PubMed  CAS  Google Scholar 

  110. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fc receptors in end-stage renal disease.. N Engl J Med 1990; 322: 717–22.

    Article  PubMed  CAS  Google Scholar 

  111. Henderson LW, Koch KM, Dinarello CA, Shaldon S. Hemodialysis hypotension: the interleukin hypothesis. Blood Purif 1983; 1: 3–8.

    Article  CAS  Google Scholar 

  112. Dinarello CA. Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992; 41: 683–94.

    Article  PubMed  CAS  Google Scholar 

  113. Lonnemann G, Van Der Meer JW, Cannon JG, et al Induction of tumor necrosis factor during extracorporeal blood purification (letter). N Engl J Med 1987; 317: 963–4.

    Article  PubMed  CAS  Google Scholar 

  114. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37: 116–25.

    Article  PubMed  CAS  Google Scholar 

  115. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954–60.

    Article  PubMed  CAS  Google Scholar 

  116. Cavaillon JM, Poignet JL, Fitting C, Delons S. Serum interleukin-6 in long-term hemodialyzed patients. Nephron 1992; 60: 307–13.

    Article  PubMed  CAS  Google Scholar 

  117. Powell AC, Bland LE, Oettinger CW, et al Lack of plasma interleukin-1 beta or tumor necrosis factor-alpha elevation during unfavorable hemodialysis conditions. J Am Soc Nephrol 1991; 2: 1007–13.

    PubMed  CAS  Google Scholar 

  118. Haran N, Bar-Khayim Y, Frensdorff A, Barnard G. Tumor necrosis factor (TNF alpha) binding protein: interference in immunoassays of TNF alpha. Kidney Int 1991; 40: 1166–70.

    Article  PubMed  CAS  Google Scholar 

  119. Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, Bade F, Delons S, Kazatchkine MD. In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989; 35: 1212–18.

    Article  PubMed  CAS  Google Scholar 

  120. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Influence of first and long-term dialysis on uraemia-associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol Dial Transplant 1991; 6: 349–57.

    Article  PubMed  CAS  Google Scholar 

  121. Schindler R, Linnenweber S, Schulze M, et al Gene expression of interleukin-1 beta during hemodialysis. Kidney Int 1993; 43: 712–21.

    Article  PubMed  CAS  Google Scholar 

  122. Roccatello D, D’Alfonso S, Peruccio D, et al Induction of mRNA for tumor necrosis factor alpha in hemodialysis. Kidney Int Suppl 1993; 39: S144–8.

    PubMed  CAS  Google Scholar 

  123. Pertosa G, Gesualdo L, Tarantino EA, Ranieri E, Bottalico D, Schena FP. Influence of hemodialysis on interleukin-6 production and gene expression by peripheral blood mononuclear cells. Kidney Int Suppl 1993; 39: S149–53.

    PubMed  CAS  Google Scholar 

  124. Dinarello CA. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int Suppl 1992; 38: 568–77.

    Google Scholar 

  125. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992; 42: 663–7.

    Article  PubMed  CAS  Google Scholar 

  126. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-lbeta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890–6.

    Article  PubMed  CAS  Google Scholar 

  127. Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA. Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990; 37: 85–93.

    Article  PubMed  CAS  Google Scholar 

  128. Sunder-Plassmann G, Sedlacek PL, Sunder-Plassmann R, et al Anti-interleukin-1 alpha autoantibodies in hemodialysis patients. Kidney Int 1991; 40: 787–91.

    Article  PubMed  CAS  Google Scholar 

  129. Lonnemann G, Behme TC, Lenzner B, et al Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria. Kidney Int 1992; 42: 61–8.

    Article  PubMed  CAS  Google Scholar 

  130. Haeffner-Cavaillon N, Jahns G, Poignet JL, Kazatchkine MD. Induction of interleukin-1 during hemodialysis. Kidney Int Suppl 1993; 39: S139–43.

    PubMed  CAS  Google Scholar 

  131. Kumano K, Yokota S, Nanbu M, Sakai T. Do cytokine-inducing substances penetrate through dialysis membranes and stimulate monocytes? Kidney Int 1993; 43: S205–8.

    Article  Google Scholar 

  132. Urena P, Herbelin A, Zingraff J, et al Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in vitro haemodialysis. Nephrol Dial Transplant 1992; 7: 16–28.

    PubMed  CAS  Google Scholar 

  133. Mege JL, Olmer M, Purgus R, et al Haemodialysis membranes modulate chronically the production of TNF alpha, IL-1 beta and IL-6. Nephrol Dial Transplant 1991; 6: 868–75.

    Article  PubMed  CAS  Google Scholar 

  134. Cala S, Maozuran R, Kordic D. Negative effect of uraemia and cuprophane haemodialysis on natural killer cells. Nephrol Dial Transplant 1990; 5: 437–40.

    Article  PubMed  CAS  Google Scholar 

  135. Zaoui P, Hakim R. Natural killer cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 1993; 43: 1298–1305.

    Article  PubMed  CAS  Google Scholar 

  136. Deppish R, Ritz E, Hansch GM, Schols M, Rauterberg EW. Biocompatibility. Perspectives in 1993. Kidney Int Suppl 1994; 45: S77–84.

    Google Scholar 

  137. Tielemans CH, Madhoun P, Lenaers M, Schandene L, Goldman M, Vanherweghein JL. Anaphylactoid reactions on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990; 38: 982–4.

    Article  PubMed  CAS  Google Scholar 

  138. Bommer J, Ritz E. Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis: a review. Artif Organs 1987; 11: 111–7.

    Article  PubMed  CAS  Google Scholar 

  139. Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311: 878–82.

    Article  PubMed  CAS  Google Scholar 

  140. Oppermann M, Kurts C, Zierz R, Quentin E, Weber Mh, Gotze O. Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Kidney Int 1991; 40: 939–47.

    Article  PubMed  CAS  Google Scholar 

  141. Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HS. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879–88.

    Article  PubMed  CAS  Google Scholar 

  142. Chenoveth DE, Cheung AK, Henderson LW. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983; 24: 764–9.

    Article  Google Scholar 

  143. Kazatchkine MD, Carreno MP. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988; 9: 30–5.

    Article  PubMed  CAS  Google Scholar 

  144. Cheung AK, Parker CJ, Wilcox L, Janatova J. Activation of the alternative pathway of complement by cellulosic hemodialysis membranes. Kidney Int 1989; 36: 257–65.

    Article  PubMed  CAS  Google Scholar 

  145. Cheung AK, Parker CJ, Wilcox LA, Janatova J. Activation of complement by hemodialysis mebranes: Polyacrilonitrile binds more C3a than cuprophan. Kidney Int 1990; 37: 1055–9.

    Article  CAS  Google Scholar 

  146. Carreno MP, Labarre D, Maillet F, Josefowicz M, Kazatchkine MD. Regulation of the human alternative complement pathway: Formation of a tertiary complex between factor H, surface bound C3b and chemical groups on nonactivating surfaces. Eur J Immunol 1989; 19: 2145–50.

    Article  PubMed  CAS  Google Scholar 

  147. Lesavre PH, Muller-Eberhard HJ. Mechanism of action of factor D of the alternative complement pathway. J Exp Med 1978; 148: 1498–1509.

    Article  PubMed  CAS  Google Scholar 

  148. Volanakis JE, Barnum SR, Giddens M, Galla JH. Renal filtration and catabolism of complement protein D. N Engl J Med 1985; 312: 395–9.

    Article  PubMed  CAS  Google Scholar 

  149. Pascual M, Schifferli JA. Adsorption of complement factor D by polyacrilonitrile dialysis membranes. Kidney Int 1993; 43: 903–11.

    Article  PubMed  CAS  Google Scholar 

  150. Lonnemann G, Bingel M, Floege J, Koch KM, Shah don S, Dinarello CA. Detection of endotoxin-like interleukin- I-inducing activity during in vitro dialysis. Kidney Int 1988; 33: 29–35.

    Article  PubMed  CAS  Google Scholar 

  151. Laude-Sharp M, Caroff M, Simard L, Pusineri C, Kazatchkine MD, Haeffner-Cavaillon N. Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney Int 1990; 38: 108–994.

    Article  Google Scholar 

  152. Laude-Sharp M, Haeffner-Cavaillon N, Caroff M, Lantreibecq F, Pusineri C. Kazatchkine MD. Dissociation between the interleukin 1-inducing capacity and Limulus reactivity of lipopolysaccharides from gram-negative bacteria. Cytokine 1990; 2: 253–8.

    Article  PubMed  CAS  Google Scholar 

  153. Urena P, Herbelin A, Zingraff J, Lair M, Man NK, Descamps-Latscha B, Drueke T. Permeability of cellulosic and non cellulosic membranes to endotoxin subunits and cytokine production during in vitro haemodialysis. Nephrol Dial Transplant 1992; 7: 16–28.

    PubMed  CAS  Google Scholar 

  154. Evans RC, Holmes O. In vitro study of the transfer of cytokine-inducing substances across selected high-flux hemodialysis membranes. Blood Purif 1991; 9: 92–101.

    Article  PubMed  CAS  Google Scholar 

  155. Lonnemann G, Mahiout A, Schindler R, Colton CK. Pyrogen retention by the polyamide membranes. Contrib Nephrol 1992; 96: 47–63.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Bétrice Descamps-Latscha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Jungers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Descamps-Latscha, B., Jungers, P. (1998). Elements of applied immunology for the intensive care unit and chronic uremia-related disorders. In: Critical Care Nephrology. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5482-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5482-6_8

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6306-7

  • Online ISBN: 978-94-011-5482-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation